Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2018

View Archived Issues

Vyera initiates phase I study of TUR-006 as treatment for toxoplasmosis

FDA awards orphan drug status to Abeona's ABO-202

FDA grants priority review to migalastat NDA

Dare Bioscience obtains license to Strategic Science & Technologies' SST-6007

FDA approves Icon Bioscience's Dexycu for inflammation associated with cataract surgery

Inovio Pharmaceuticals and The Wistar Institute to jointly develop vaccines for TB and malaria

SGSH gene therapy shows biological activity in phase I/II MPS type III A trial

Shire's SHP-647 granted orphan drug status for Crohn's disease in pediatric population

Cancer Targeted Technology, Advanced Accelerator Applications enter CTT-1057 license agreement

First-in-human results presented for SBC-103 in children with MPS IIIB

Foundation Fighting Blindness to support development of ProQR's candidate for Usher syndrome 2A

Sirenas and BMS enter multitarget research collaboration

FDA approves Symdeko to treat underlying cause of cystic fibrosis

Opiant Pharmaceuticals announces plans for intranasal nalmefene

Audentes Therapeutics begins dosing in phase I/II VALENS study

Kadmon reports phase II data on KD-025 in IPF

Avid Bioservices and Oncologie enter agreement for PS-targeting program

WntResearch revises design of planned phase II study of Foxy-5

Clenbuterol improves muscle function in patients with late-onset Pompe disease

Nerviano Medical Sciences patents new choline kinase inhibitors

Shenzhen Targetrx Biotechnology divulges novel EGFR mutant inhibitors

Shionogi identifies new dopamine D3 receptor antagonists

EC approves Diurnal's Alkindi as replacement therapy for pediatric adrenal insufficiency

Cerecor to acquire Avadel's pediatric business

Beijing Jacobio Pharmaceuticals patents AURKA and FADK 1 inhibitors

MabVax Therapeutics reports interim data from phase I study of MVT-5873

CPCI discovers new triptolide derivatives for the treatment of cancer

Erytech expands eryaspase program into triple-negative breast cancer

Nipro and TC BioPharm collaborate to codevelop novel CAR-T product for cancer

Methylene blue can be used to block Plasmodium falciparum transmission

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...